Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOL-1: OTX-TKI (Axitinib Implant) for nAMD
NCT06223958Phase 3Active, not recruiting
- Sponsor
- Ocular Therapeutix
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of axitinib in neovascular age-related macular degeneration (NVAMD), sponsored by Ocular Therapeutix. Started Jan 2024; status: active, not recruiting.
02
Drugs
axitinib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06223958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223958.